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The 19-amino acid conopeptide (-TIA) was shown
previously to antagonize noncompetitively 1B-adrener-
gic receptors (ARs). Because this is the first peptide
ligand for these receptors, we compared its interactions
with the three recombinant human 1-AR subtypes (1A,
1B, and 1D). Radioligand binding assays showed that
-TIA was 10-fold selective for human 1B- over 1A- and
1D-ARs. As observed with hamster 1B-ARs, -TIA de-
creased the number of binding sites (Bmax) for human
1B-ARs without changing affinity (KD), and this inhibi-
tion was unaffected by the length of incubation but was
reversed by washing. However, -TIA had opposite ef-
fects at human 1A-ARs and 1D-ARs, decreasing KD
without changing Bmax, suggesting it acts competitively
at these subtypes. -TIA reduced maximal NE-stimu-
lated [3H]inositol phosphate formation in HEK293 cells
expressing human 1B-ARs but competitively inhibited
responses in cells expressing 1A- or 1D-ARs. Trunca-
tion mutants showed that the amino-terminal domains
of 1B- or 1D-ARs are not involved in interaction with
-TIA. Alanine-scanning mutagenesis of -TIA showed
F18A had an increased selectivity for 1B-ARs, and F18N
also increased subtype selectivity. I8A had a slightly
reduced potency at 1B-ARs and was found to be a com-
petitive, rather than noncompetitive, inhibitor in both
radioligand and functional assays. Thus -TIA noncom-
petitively inhibits 1B-ARs but competitively inhibits
the other two subtypes, and this selectivity can be in-
creased by mutation. These differential interactions do
not involve the receptor amino termini and are not be-
cause of the charged nature of the peptide, and isoleu-
cine 8 is critical for its noncompetitive inhibition at
1B-ARs.
1-Adrenergic receptors (ARs)
1 are heptahelical G protein-
coupled receptors (GPCRs) that mediate important physiolog-
ical responses to norepinephrine (NE) and epinephrine as di-
verse as smooth muscle contraction, glycogenolysis, and
myocardial inotropy (1, 2). Molecular cloning and pharmaco-
logical studies have identified three subtypes of 1-ARs: 1A-,
1B-, and 1D-ARs (3–10). Although all three 1-AR subtypes
signal through the same Gq/11 signaling pathway (11), 1-AR
subtypes can differ in their tissue distributions (1), cellular
localization (12, 13), activation of transcriptional responses
(14), and association with intracellular proteins (15–17), sug-
gesting that 1-AR subtypes perform specific physiological
functions. Furthermore, recent data obtained from both 1-AR
overexpressed (18–21) and knockout mice (22–25) indicate that
1-ARs play important physiological roles in the cardiovascular
system and central nervous system. However, attempts to
pharmacologically isolate specific responses to particular sub-
types have proven difficult because of the lack of highly 1B-
AR-selective antagonists.
Recently, a 19-amino acid conopeptide, -TIA, was isolated
from the venom of the fish-hunting cone snail Conus tulipa (26,
27). This highly charged peptide (amino acid sequence FN-
WRCCLIPACRRNHKKFC) forms a distinct structure with two
disulfide bonds between cysteines 5 and 11 and cysteines 6 and
19 (26). -TIA was found to be a selective 1-AR antagonist, as
it inhibited 1-AR-mediated contraction of rat vas deferens
without affecting ATP or 2-AR-mediated responses (26, 27).
Studies on recombinant hamster 1B-ARs found that increas-
ing concentrations of -TIA progressively reduced the density
of radioligand binding sites without changing radioligand af-
finity, suggesting that -TIA is a noncompetitive, possibly al-
losteric, inhibitor of 1B-ARs. In addition, radioligand binding
assays performed using recombinant rodent 1-AR subtypes
revealed a 2–5-fold higher affinity for -TIA at 1B-ARs (27).
Allosteric modulators of GPCRs have received increasing
attention over the last few years for their potential specificity
and lack of undesirable effects (28). Unlike drugs that act on
the conserved orthosteric binding sites of closely related recep-
tor subtypes, actions of allosteric modulators have been found
to be highly specific for particular receptor subtypes, because
they often interact with less highly conserved sites (28). Al-
though -TIA also inhibits rodent 1A- and 1D-ARs, its mode of
inhibition has not yet been determined. In addition, its effects
on human subtypes are still unknown.
In this study, we compared the effects of -TIA at all three
human 1-AR subtypes stably expressed in human embryonic
kidney (HEK293) cells. We found that -TIA acts noncompeti-
tively at human 1B-ARs but competitively at 1A- and 1D-ARs
and that the isoleucine at position 8 in -TIA is required for
noncompetitive inhibition. In addition, -TIA is the first highly
selective antagonist for human 1B-ARs, which will be useful in
functional characterization of this receptor.
EXPERIMENTAL PROCEDURES
Materials—Materials were obtained from the following sources:
HEK293 cells, American Type Culture Collection (Manassas, VA); pen-
icillin, streptomycin, phosphate-buffered saline (PBS), ()-norepineph-
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rine (NE) bitartrate, phentolamine mesylate, Sigma; carrier-free
Na[125I], Amersham Biosciences; myo-[3H]inositol (1 mCi/ml), Ameri-
can Radiolabeled Chemicals (St. Louis, MO); Dulbecco’s modified Ea-
gle’s medium with 4.5 g/liter glucose and L-glutamine, Mediatech
(Herndon, VA); {[2--(4-hydroxyphenyl)ethylaminomethyl]tetralone}
from Dr. Giuseppe Romeo (University of Catania, Italy); [3H]prazosin,
PerkinElmer Life Sciences; Fmoc-Rink amide resin (Polymer labs, 0.73
mmol/g, Scientex Australia); Fmoc amino acids (Novabiochem).
Peptide Synthesis—-TIA and its analogs were assembled using
Fmoc chemistry. Chain assembly of the peptides was performed on a
manual shaker system using HBTU activation protocols (29) or on an
ACT396 synthesizer using HBTU in situ activation protocols. The Fmoc
protecting group was removed using 50% piperidine in dimethylform-
amide, and dimethylformamide was used as both the coupling solvent
and for flow washes throughout the cycle. Where possible, the progress
of the assembly was monitored by quantitative ninhydrin monitoring
(30). Peptide was deprotected and cleaved from the resin by stirring at
room temperature in trifluoroacetic acid:H2O:triisopropyl silane:
ethanedithiol (90:5:2.5:2.5) for 2–3 h. Cold diethyl ether was then added
to the filtered mixture, and the precipitated peptide was collected by
centrifugation. The final product was dissolved in 50% aqueous aceto-
nitrile and lyophilized to yield a white solid. The crude, reduced peptide
was examined by reverse phase high pressure liquid chromatography
for purity, and the correct molecular weight was confirmed by electro-
spray mass spectrometry. Pure, reduced peptide was oxidized using
30% isopropyl alcohol, 0.1 M ammonium bicarbonate, pH 7.7, for 24 h,
and then the major peak was purified to95% purity and characterized
by reverse phase high pressure liquid chromatography/mass spectrom-
etry prior to further use.
Cell Culture and Transfection—HEK293 cells stably expressing hu-
man 1A- (31), 1B- (7), or 1D- (9)ARs have been previously described
(32). Cells were propagated in Dulbecco’s modified Eagle’s medium
containing 10% calf serum, 4.5g/liter glucose, 100 mg/liter streptomy-
cin, and 105 units/liter penicillin at 37 °C in a humidified atmosphere
with 5% CO2. Confluent 150-mm plates were subcultured at a ratio of
1:4 or 1:6 for transfection and cultured for 24–48 h. For cells expressing
N-truncated constructs (see below), HEK293 cells were transfected with
10 g of DNA of each construct for 3 h using Superfect® transfection
reagent and were used for experimentation 48–72 h after transfection.
Membrane Preparation—Confluent 150-mm plates were washed
with PBS (10 mM phosphate buffer, 2.7 mM KCl, 137 mM NaCl, pH 7.4)
and harvested by scraping. Cells were collected by centrifugation at
30,000  g for 10 min, resuspended in PBS, and homogenized with a
Polytron. This process was then repeated, and final membranes were
collected in 0.5 ml of PBS.
Radioligand Binding—Receptor density was determined by satura-
tion binding assays with the 1-AR-specific antagonist
125I-BE (20–800
pM) (33) or [3H]prazosin (200–5000 pM) (34). Membranes were incu-
bated with the indicated concentrations of either 125I-BE or [3H]prazo-
sin at 37 °C in a water bath for 20 min. After incubation, samples were
filtered through a wet Whatman GF/B paper under vacuum. Filter
papers were washed twice with cold wash buffer (10 mM Tris-HCl, pH
7.4), and radioactivity was measured by gamma counting. Nonspecific
binding was determined as binding in the presence of 10 M phentola-
mine. For the washout experiments, membranes were aliquoted into
two sets and incubated with or without 30 nM -TIA. For each wash,
each sample was diluted 2.5-fold with PBS, homogenized, and resus-
pended in the appropriate volume of PBS. 125I-BE was added with or
without phentolamine; samples were incubated at 37 °C and filtered,
and radioactivity was measured by gamma counting. The amount of
specific binding inhibited by 30 nM -TIA was calculated after each
wash. Nonspecific binding was defined as binding remaining in the
presence of 10 M phentolamine.
[3H]InsP Formation—Accumulation of [3H]inositol phosphates (In-
sPs) was determined in confluent 96-well plates as described previously
(35). Cells were loaded with [3H]inositol (1 Ci/well) at the time of
seeding and grown for 1–2 days until confluent. On the day of the
experiments, wells were washed carefully with Krebs-Ringer bicarbon-
ate (KRB) buffer (120 mM NaCl, 5.5 mM KCl, 2.5 mM CaCl2, 1.2 mM
NaH2PO4, 1.2 mM MgCl2, 20 mM NaHCO3, 11 mM glucose, 0.029 mM
Na2EDTA) containing 10 mM LiCl, and then incubated with 0.1 ml of
Li-KRB containing drugs at the indicated concentrations. Conopeptides
were prepared in 50 l of Li-KRB and added into the wells before
adding an equal volume of Li-KRB containing appropriate NE concen-
trations. After incubating at 37 °C (in 95%O2/5%CO2) for 1 h, reactions
were stopped by adding 10 mM formic acid. Samples were sonicated for
10 s, and [3H]InsPs were isolated by anion exchange chromatography as
described (35). Data were normalized to % maximal stimulation caused
by 100 M NE alone. NE caused no stimulation of [3H]InsP formation in
nontransfected HEK293 cells at concentrations up to 300 M. Schild
plot was generated as described previously (36).
Generation of Amino-terminal Truncated Receptors—Amino-termi-
nally truncated human 1D-ARs (
1–79) were constructed in pRSVICAT
vectors as described previously (37). Amino-terminally truncated hu-
man 1B-ARs (
1–38) were generated by PCR using specific primers on
human 1B-AR cDNA in pDT, subcloned, and sequenced.
Data Analysis—Data are expressed as mean  S.E. of results ob-
tained from the indicated number of observations. For radioligand
binding, calculations of KD and Bmax for saturation analysis, and IC50
values for inhibition of specific binding by peptides were fit by nonlinear
regression using Prism (GraphPad). Global fitting was used to define
the mode of inhibition of -TIA from saturation analysis (either shared
KD or shared Bmax). Concentration-response curves for stimulation of
[3H]InsP formation were also analyzed by nonlinear regression. One-
way analysis of variance with post hoc t test performed by the Tukey
method was used where indicated. Values of p  0.05 were considered
significant.
RESULTS
-TIA Inhibition of Specific 125I-BE Binding in HEK293 Cell
Membranes Expressing Human 1A-, 1B-, or 1D-ARs—Be-
cause -TIA showed noncompetitive inhibition at hamster 1B-
ARs (26), we investigated the inhibitory effects of -TIA at
human 1A-, 1B-, and 1D-ARs. Increasing concentrations of
-TIA inhibited specific 125I-BE binding to membranes pre-
pared from HEK293 cells stably expressing individual 1-AR
subtypes (Fig. 1). However, unlike the limited selectivity ob-
served previously with the rodent clones (27), -TIA was more
potent and showed a 10-fold 1B selectivity. IC50 values for
-TIA were 18 nM (logIC50 7.4  0.08) at 1A-ARs; 2 nM
(logIC50 8.4  0.10) at 1B-ARs; and 25 nM (logIC50 7.3 
0.13) at 1D-ARs. The difference in potency of -TIA was sig-
nificant between 1B-ARs and 1A- and 1D-ARs (p 0.001) but
not between 1A-ARs and 1D-ARs.
Mode of Inhibition—To determine whether -TIA acts non-
competitively at each human 1-AR subtype, saturation bind-
ing assays with the selective antagonist 125I-BE were per-
formed on membranes prepared from HEK293 cells expressing
individual 1-AR subtypes in the presence or absence of 100 nM
-TIA (Fig. 2). Nonlinear regression analysis was used to de-
termine whether inhibition by -TIA was competitive (shared
Bmax) or noncompetitive (shared KD). It was found that inhibi-
tion of specific 125I-BE binding to human 1B-ARs was clearly
noncompetitive (p  0.005), whereas inhibition of binding to
human 1A- and 1D-ARs was competitive (p 0.01 for 1A-and
p  0.05 for 1D-ARs). To confirm that these findings could be
generalized to another 1-AR radioligand, the same experi-
ments were repeated using [3H]prazosin in place of 125I-BE. In
agreement with our previous experiments, -TIA noncompeti-
tively inhibited 1B-AR binding (p 0.005) but was competitive
at the 1A-AR (p  0.05) and 1D-AR (p  0.01) subtypes (data
FIG. 1. Concentration-dependent inhibition of specific 125I-BE
binding by -TIA in membranes prepared from HEK293 cells
stably transfected with individual 1-AR subtypes. Symbols rep-
resent the mean  S.E. of four determinations.
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not shown). Therefore, these observations suggest -TIA acts
differently at the 1-AR subtypes as a noncompetitive inhibitor
at human 1B-ARs but as a competitive inhibitor at 1A- and
1D-ARs.
-TIA Binds to the Human 1B-AR in a Reversible Manner—
Although previous experiments suggested that -TIA binds to
human 1B-ARs noncompetitively, it is unclear if this binding
is also reversible. To examine this, HEK293 cells stably ex-
pressing human 1B-ARs were preincubated with increasing
concentrations of -TIA for 2 h. As shown in Fig. 3A, preincu-
bation had no effect on -TIA potency for inhibiting 125I-BE
binding, demonstrating that -TIA acts in a time-independent
manner. In addition, repeated washes slowly reversed -TIA
inhibition of 125I-BE binding, supporting the reversibility of
this interaction (Fig. 3B). Thus, these data indicate -TIA binds
in a noncompetitive, reversible manner to the human 1B-AR,
which suggests that -TIA is likely to be an allosteric inhibitor.
-TIA Inhibition of NE-stimulated [3H]InsP Formation—Ra-
dioligand binding studies suggested that -TIA binds differen-
tially to the human 1-AR subtypes, and we wanted to deter-
mine whether similar results could be obtained with functional
responses. To address this question, the ability of -TIA in
inhibiting NE-stimulated [3H]InsP formation in HEK293 cells
stably expressing individual 1-AR subtypes was examined.
Cells were preincubated with [3H]inositol and stimulated with
increasing concentrations of NE for 1 h in the absence or
presence of various concentrations of -TIA. As shown in Fig. 4,
increasing concentrations of -TIA caused parallel rightward
shifts in the NE concentration-response curve for 1A- and
1D-ARs, without causing significant decreases in the NE max-
imal responses. From the concentration-response curves,
Schild plots were constructed, and -TIA pA2 values were cal-
culated as 7.0 for 1A-ARs and 6.8 for 1D-ARs, which were
similar to the KD values generated from radioligand binding
studies. Slope values were not significantly different from unity
at either subtype, suggesting that -TIA binds to a single pop-
ulation of binding sites. In direct contrast, increasing con-
centrations of -TIA caused sequential decreases in the NE
maximal response to 1B-AR activation, indicative of noncom-
petitive inhibition. These findings further support the hypoth-
esis that -TIA acts as a noncompetitive inhibitor at human
1B-ARs but competitively inhibits human 1A- and 1D-ARs.
Role of the 1-AR Amino Terminus in -TIA Binding—Pre-
vious studies (38) have reported that the amino-terminal re-
gions of GPCRs are involved in the formation of the binding
pocket for peptide ligands. The amino-terminal regions of
1-AR subtypes differ in size and display very little sequence
homology (37, 39). To determine whether these domains are
important for -TIA binding, we compared the potency of -TIA
in inhibiting specific 125I-BE binding to both amino-terminal
truncated and full-length 1B- and 1D-ARs. As shown in Fig. 5,
-TIA inhibited specific 125I-BE binding to full-length and ami-
no-terminally truncated 1B- and 1D-ARs with similar po-
tency, suggesting that the amino-terminal domains of these
1-AR subtypes are not important for -TIA binding. We did not
perform experiments using truncated 1A-ARs, as the 1A-AR
has a very short amino terminus (25 amino acids) relative to
the 1B- (45 amino acids) and 1D-AR (95 amino acids) subtypes
and is unlikely to be involved in -TIA binding given that the
amino-terminal regions of 1B-and 1D-ARs were not involved.
Effect of Alanine Scanning Mutagenesis on Selectivity of
-TIA for 1-AR Subtypes—To examine the importance of indi-
vidual amino acids in conferring 1-AR subtype selectivity,
-TIA was subjected to alanine scanning mutagenesis of non-
cysteine residues. -TIA and alanine-substituted analog poten-
cies for inhibiting 125I-BE binding at 1-AR subtypes are dis-
played in Fig. 6. The majority of the peptide analogs examined
retained their 1B-AR selectivity, although it was somewhat
lower than that of the parent compound. In a few instances,
there was a loss of 1B-AR selectivity (R4A and I8A). A number
of analogs (F1A, L7A, and R12A) bound with lower affinity to
1B-ARs than -TIA but had a higher degree of selectivity
between the 1B-ARs and 1A- and 1D-AR subtypes. Most
interesting, the F18A mutation resulted in an increase in sub-
type selectivity without a loss in 1B-AR affinity (Figs. 6 and 7).
Mutants with high 1B-AR selectivity (F1A, N14A, K16A, and
F18A) (Fig. 7) maintained their noncompetitive inhibition at
1B-ARs by progressively decreasing Bmax without affecting KD
(Fig. 8). These results suggest that modification of -TIA can
increase subtype selectivity without changing its noncompeti-
tive properties in inhibition of 1B-ARs. Among all the alanine-
substituted analogs, R4A had the lowest affinity for all three
1-AR subtypes. The R4A mutation was shown previously to
impart low affinity binding to hamster 1B-ARs (27), because of
a disruption between the positively charged arginine on -TIA
and a complementary negatively charged residue on the 1B-
AR. In support of these findings, alanine substitution of argi-
nine at positions 12 and 13 resulted in a decrease in -TIA
inhibitory potency (Fig. 6). Therefore, these data suggest that
the charged nature of the -TIA plays a role in imparting high
affinity interactions with the 1-AR subtypes but does not
contribute to its subtype selectivity.
Effect of Amino Acid Substitution at Position 18 in -TIA—In
the previous figure, the F18A-TIA peptide analog showed an
increased subtype selectivity in comparison to -TIA without
loss in affinity. To determine whether the 1-AR subtype selec-
tivity of -TIA could be further enhanced, the phenylalanine at
position 18 was modified by amino acid substitution. The posi-
tion 18-modified peptide analogs and their potencies for inhib-
iting 125I-BE binding to 1-AR subtypes are listed in Table I.
All position 18 analogs had decreased potencies for inhibiting
125I-BE binding to 1B-ARs in comparison to the parent pep-
FIG. 2. Saturation binding of
125I-BE to HEK293 membranes ex-
pressing 1-AR subtypes in the pres-
ence or absence of 100 nM -TIA. Sym-
bols represent the mean  S.E. of three
experiments performed in duplicate.
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tide. In addition, amino acid substitution did not enhance the
binding to the 1A- or 1D-AR subtypes nor were there any
further increases in 1-AR subtype selectivity relative to the
F18A analog. Of all the peptide analogs screened, the F18N
analog displayed the highest level of subtype selectivity, with a
30-fold difference in potency between 1B-ARs over 1A- and
1D-AR subtypes. However, in comparison to the F18A analog,
F18N bound to 1B-ARs with lower affinity. Therefore, substi-
tuting the phenylalanine at position 18 with alanine or aspar-
agine increases the 1-AR subtype selectivity of -TIA but does
not increase the 1B-AR binding affinity.
In the previous alanine scanning study, a number of the
analogs (F1A, L7A, P9A, N14A, K16A, and K17A) showed an
equal or greater degree of 1-AR subtype selectivity in compar-
ison to -TIA. Thus, -TIA analogs containing both the F18A
and an additional alanine substitution were created to attempt
to enhance the 1-AR subtype selectivity. Of the six analogs
tested (F1A/F18A, L7A/F18A, P9A/F18A, N14A/F18A, K16A/
F18A, and K17A/F18A), only the K17A/F18A (log IC50 1A 
5.7  0.06; 1B  7.7  0.06; 1D  6.6  0.19) and
L7A-F18A (log IC50 1A  5.2  0.10; 1B  7.3  0.11;
1D6.1 0.03) double mutants maintained a level of 1-AR
FIG. 5. Inhibition of specific 125I-BE binding by -TIA in mem-
branes from HEK293 cells expressing full-length or amino-ter-
minal truncated 1–38 1B- (left) or 
1–791D-ARs (right). Symbols
represent the mean  S.E. of three to four determinations.
FIG. 3. Reversibility of -TIA bind-
ing to 1B-ARs. A, membranes from
HEK293 cells expressing 1B-ARs were
preincubated with (f) or without (E)
-TIA for 2 h prior to examination of in-
hibition of specific 125I-BE binding. B,
HEK293 cell membranes expressing 1B-
ARs were incubated with or without 30
nM -TIA and subjected to repeated wash-
ing. Data are expressed as % of control
specific binding (f).
FIG. 4. -TIA inhibition of NE-stim-
ulated [3H]InsP formation in HEK293
cells stably expressing 1-AR sub-
types. Left, NE concentration-response
curves for [3H]InsP formation in HEK293
cells stably expressing each 1-AR sub-
type were measured in the absence or
presence of the indicated concentrations
of -TIA. Symbols represent the mean 
S.E. of 6–9 determinations. Right, Schild
plots for competitive inhibition by -TIA
in 1A- (upper, ) or 1D- (lower, )-AR
expressing cells.
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subtype selectivity equal to the F18A analog. All other double
mutant analogs were not as selective as F18A and bound with
lower affinity (data not shown). Furthermore, the L7A and
K17A mutations were combined with the F18A mutation to
attempt to enhance the selectivity of the peptide. Introducing
all three alanine mutations (L7A/K17A/F18A) failed to increase
the subtype selectivity and had significantly lower affinity (log
IC50 1A  4.8  0.27; 1B  6.9  0.13; 1D  5.7  0.08)
for the 1-AR subtypes. Therefore, these data suggest that
introducing a single alanine mutation at position 18 in -TIA
yields the highest level of 1-AR subtype selectivity, while
maintaining a high affinity interaction with the 1B-AR.
Importance of the Amino-terminal Portion of -TIA for Activ-
ity at 1-ARs—Previous studies (27) have shown that removal
of the initial three amino acids from -TIA (TIA4–19) resulted in
a decrease in the ability of -TIA to inhibit 1-AR-induced
contraction. To examine the importance of the proximal three
amino acids in maintaining 1-AR subtype selectivity of -TIA,
we compared the potency of TIA4–19 for inhibiting
125I-BE
binding to each of the three 1-AR subtypes. As shown in Fig.
6 (far right), TIA4–19 was 	10-fold more selective for the
1B-AR subtype over the 1A- and 1D-AR subtypes. However,
the affinity of TIA4–19 was at least 1000-fold lower for all three
subtypes relative to -TIA. These results suggest that removing
the proximal three amino acids from -TIA does not abrogate
the subtype selectivity of the peptide but is critical for main-
taining high affinity binding to the 1-AR subtypes.
Isoleucine 8 Is Critical for -TIA Noncompetitive Inhibition at
1B-ARs—From the alanine scanning mutagenesis shown in
Fig. 6, it is clear that the majority of -TIA analogs maintained
a moderate degree of 1-AR subtype selectivity. However, sub-
stituting isoleucine at position 8 (I8A) resulted in an abolish-
ment of -TIA selectivity (Fig. 6). From these results, we hy-
pothesized that the mode of inhibition of -TIA at 1B-ARs may
have been altered. To test this, we performed 125I-BE satura-
tion binding experiments on HEK293 cells stably expressing
1B-ARs in the absence and presence of 300 nM I8A. As ob-
served in Fig. 9A, I8A treatment had no significant effect on the
1B-AR Bmax but significantly changed the KD (Fig. 9A). These
findings directly contrast with our previous results using
-TIA, which significantly reduced the 1B-AR Bmax (Fig. 2).
Thus, we examined the ability of I8A to inhibit NE-stimulated
[3H]InsP formation in HEK293 cells stably expressing human
1B-ARs. Preincubation of cells with 3 M I8A resulted in a
10-fold parallel shift to the right in the NE concentration-
response curve without reducing the maximal response. Com-
bined with the data from the saturation analysis, our findings
suggest that isoleucine at position 8 is essential for the non-
competitive nature of -TIA at the 1B-AR subtype, and substi-
tution of this amino acid results in a complete reversal of -TIA
to a competitive antagonist at the 1B-AR.
DISCUSSION
In this study, we have shown that the conopeptide -TIA is a
highly selective 1B-AR antagonist. Through a combination of
radioligand binding and functional assays, we have demon-
strated that -TIA interacts differentially at the 1-AR sub-
types as a noncompetitive antagonist at 1B-ARs and as a
competitive antagonist at 1A- and 1D-ARs. The 1-AR amino-
terminal regions do not appear to be important for binding to
-TIA, as there were no changes observed in the -TIA binding
between amino-terminal truncated and full-length receptors.
Alanine scanning mutagenesis revealed that substituting phe-
nylalanine at position 18 resulted in a substantial increase in
subtype selectivity. In addition, substituting isoleucine at po-
sition 8 changed -TIA from being a noncompetitive antagonist
at 1B-ARs to a competitive antagonist. Taken together, these
FIG. 6. Effect of alanine substitu-
tion on the potency of -TIA in com-
peting for specific 125I-BE binding in
membranes from HEK293 cells ex-
pressing human 1-AR subtypes. Non-
cysteine amino acids of -TIA were sys-
tematically replaced with alanine as
described under “Experimental Proce-
dures.” Bars represent the mean IC50 val-
ues  S.E. calculated by nonlinear
regression.
FIG. 7. Effect of selected alanine substitution on -TIA inhibi-
tion potency. Competition curves for inhibition of 125I-BE binding by
the alanine-substituted analogs F1A (upper left), N14A (upper right),
K16A (lower left), and F18A (lower right) to HEK293 membranes ex-
pressing individual 1-AR subtypes are displayed. Symbols represent
the mean  S.E. of four determinations.
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findings indicate that -TIA is a new pharmacological tool that
can be used to distinguish between 1-AR subtypes and may
serve as a lead compound for the development of highly selec-
tive 1-AR agents.
In the past, development of therapeutic compounds that
target 1-ARs has been driven by their important roles in the
regulation of hypertension, benign prostatic hypertrophy, and
nasal congestion (1, 11). However, few drugs have been pro-
duced that can adequately differentiate between 1-AR sub-
types. The majority of 1-AR ligands developed has been shown
to be 1A-AR-selective, including WB 4101 (40), 5-methylura-
pidil (41), tamsulosin (42), and (
)-niguldipine (43). A single
highly selective 1D-AR antagonist exists, BMY 7378 (44).
However, there has yet to be developed a highly selective
1B-AR antagonist (1). The most widely used 1B-AR ligand to
date has been chloroethylclonidine (45), a site-directed alkylat-
ing agent that has been used for pharmacological characteriza-
tion of 1-AR subtypes. However, the technical difficulties as-
sociated with using chloroethylclonidine (i.e. temperature and
time dependence) have limited the usefulness of this com-
pound. Spiperone and cyclazosin (46) are 1B-AR competitive
antagonists that have been reported to be slightly selective for
1B-ARs over 1A- and 1D-ARs and therefore have limited use
in functional applications. Therefore, the need for highly selec-
tive 1B-AR has remained unfulfilled. In this study, we have
shown that -TIA is 10-fold selective for the 1B-AR subtype,
and most important, acts as a noncompetitive antagonist at
1B-ARs and as a competitive antagonist at 1A- and 1D-AR
subtypes. The dual nature of this ligand is novel for 1-AR
pharmacological agents and will be highly useful for future
studies involving characterization of 1-AR functional re-
sponses. In addition, we have shown that the subtype selectiv-
ity of this peptide can be further enhanced by modification of
specific amino acid residues. Thus, -TIA can act as a template
for the development of novel therapeutic compounds for treat-
ment of diseases associated with 1-AR stimulation.
Recent studies using transgenic and knockout mice have
implicated 1B-ARs in playing an important role in blood pres-
sure regulation (23), cardiac remodeling (19, 21, 47), glucose
homeostasis (48), and central nervous system control of loco-
motion (49). However, several studies (50) have suggested that
1A- and 1D-ARs can also contribute to the regulation of these
physiological processes. Therefore, highly selective 1B-AR an-
tagonists would be extremely valuable in clarifying the relative
contributions of each subtype in regulating these important
FIG. 8. Noncompetitive binding of alanine-substituted -TIA analogs to 1B-ARs.
125I-BE saturation binding was performed on HEK293
membranes expressing 1B-ARs in the presence or absence of increasing concentrations of F1A (upper left), N14A (upper right), K16A (lower left),
or F18A (lower right). Symbols represent the mean  S.E. of four determinations.
TABLE I
Comparison of the potencies of F18A and its various amino acid-
substituted analogs for human 1-AR subtypes
The Phe-18 residue of -TIA was systematically replaced with differ-
ent amino acids, and constructs were assayed for inhibiting specific
125I-BE binding to membranes prepared from HEK293 cells stably
expressing individual receptor subtypes. Data are shown as mean log
IC50  S.E. of 2–4 determinations.
Mutants 1A-ARs 1B-ARs 1D-ARs
F18A 6.4  0.19 8.2  0.11 7.2  0.14
F18D 5.5  0.13 7.0  0.08 6.2  0.07
F18E 5.9  0.06 7.7  0.07 6.6  0.10
F18G 5.9  0.07 7.0  0.10 6.4  0.12
F18K 6.1  0.04 7.6  0.07 6.8  0.11
F18N 6.1  0.06 7.8  0.07 6.3  0.11
F18P 6.1  0.13 7.0  0.06 6.4  0.07
F18R 6.2  0.08 7.5  0.09 7.1  0.09
F18S 6.1  0.04 7.7  0.15 6.9  0.09
F18V 6.5  0.10 7.5  0.08 7.0  0.09
F18W 6.4  0.07 7.8  0.10 6.7  0.12
F18Y 6.2  0.06 7.5  0.12 6.5  0.06
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biological functions. Increasing concentrations of agonist can
overcome -TIA inhibition of 1A- and 1D-ARs but are unable
to surmount -TIA noncompetitive antagonism at 1B-ARs.
Therefore, taking advantage of the differential modes of inhi-
bition of -TIA will allow us to distinguish functional differ-
ences between 1-AR subtypes and may provide some clarity to
current debates concerning 1-AR functional responses.
The most interesting aspect of this study was that -TIA
binds to closely related receptor subtypes through different
mechanisms. -TIA bound to 1B-ARs in a noncompetitive,
reversible manner but displayed competitive antagonism at
1A- and 1D-ARs. These data suggest that -TIA may be a
negative allosteric modulator at 1B-ARs, although further
studies will be needed to substantiate this conclusion. This is
similar to what has been observed in previous studies investi-
gating benzodiazepines at all three 1-AR subtypes (51) or
amiloride analogs (52) binding to 1A-ARs. Therefore, under-
standing the mechanism by which -TIA binds to each subtype
may provide useful information for the development of novel
1-AR subtype-selective drugs. Theoretically, the highly
charged and rigid structure of -TIA should limit accessibility
to the binding site of the endogenous ligand in the hydrophilic
pocket formed by the transmembrane domains (2). Therefore,
we hypothesized that the amino-terminal domains may play a
role in -TIA binding to 1-ARs. For example, the long amino
terminus of the lutrophin/choriogonadotropin receptor confers
high affinity peptide ligand binding (38). However, no substan-
tial differences in -TIA binding were observed when compar-
ing amino-terminal truncated receptors to full-length recep-
tors, suggesting that the amino terminus does not contribute to
either the affinity or competitive/noncompetitive nature of this
ligand. Previous studies have found that peptide ligands in-
cluding angiotensin (53), neuropeptide Y (54), and vasopression
(55) bind to their respective GPCRs through a mechanism that
involves the extracellular domains. The 1-AR extracellular
loop domains are highly divergent among subtypes (25–40%
homology) and thus may be responsible for the differential
modes of inhibition of -TIA between the 1-AR subtypes. In
fact, mutation of three adjacent amino acids in the second
extracellular loop of 1B-ARs to corresponding amino acids
found in the 1A-AR second extracellular loop was able to
confer 1A-AR antagonist binding properties to the 1B-AR (56).
Therefore, these findings suggest that -TIA may bind to a
novel binding site on 1-ARs, which may be partially formed by
the extracellular loops of the receptor.
Peptide ligands for GPCRs are routinely modified in order to
enhance subtype selectivity and/or increase the potency of the
ligand at the receptor (57). Normally, amino acid scan/substi-
tution and partial truncation of a parent peptide ligand are
performed in order to determine the key residues involved in
the biological activity of the peptide. In previous studies, ala-
nine scanning of neurotensin revealed that leucine at position
13 confers high affinity binding (58). In these studies, alanine
scanning mutagenesis of -TIA revealed that alanine substitu-
tion of phenylalanine at position 18 enhances the subtype se-
lectivity of -TIA, while maintaining the noncompetitive nature
and high affinity interaction of -TIA at 1B-ARs. However,
alternate amino acid substitutions at position 18 failed to cre-
ate any increase in 1-AR subtype selectivity. Charged residues
within the peptide ligand have been shown to be important in
peptide-receptor interactions. For example, alanine substitu-
tion of arginine at positions 8 or 9 resulted in a 10–100-fold
decrease in neurotensin binding affinity (58). Charged arginine
residues at positions 4, 12, and 13 in -TIA appear to be
important for conferring high affinity binding, as alanine sub-
stitution reduced the potency of -TIA at all three human
1-AR subtypes by 6–400-fold. In addition, the three amino-
terminal amino acids of -TIA appear to be important, as ami-
no-terminal truncation results in a decrease in -TIA binding
affinity to all three subtypes. Combined with previous reports
of the NMR structure of -TIA (26), these data suggest that the
amino terminus of -TIA forms a flexible open end that serves
to extend the backbone, therein facilitating the interaction of
-TIA with the receptor. Taken together, our results may pro-
vide useful structural information for further analyses of pep-
tide conformation using various conformational constraint
approaches.
Another interesting finding of this study was that alanine
substitution of isoleucine at position 8 changed -TIA from a
noncompetitive antagonist at the 1B-AR to a competitive an-
tagonist. In previous studies investigating calcitonin gene-re-
lated peptide (59) and opioid agonists (60), minor modifications
in amino acid sequence have resulted in dramatic differences in
ligand binding properties. Despite these findings, considerable
efforts are still required to obtain a full understanding of the
structure-activity relationship between -TIA and the 1-AR
subtypes.
In summary, we found that -TIA is a noncompetitive inhib-
itor at human 1B-ARs, whereas at 1A- and 1D-AR subtypes it
acts as a competitive inhibitor. Replacing isoleucine with ala-
nine at position 8 converts the noncompetitive interaction of
-TIA at 1B-ARs to a competitive interaction, supporting the
conclusion that the binding site of -TIA is in close proximity to
that of the endogenous ligand. By taking advantage of the
selective nature and differential modes of inhibition of -TIA,
this peptide should prove valuable in elucidating the relative
contribution of 1-AR subtypes in mediating different func-
tional responses.
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